Immuno-Oncology Drugs Market

Table of Content

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions

2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis

2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources

2.4.2. Primary Research
2.4.2.1. Introduction

2.4.2.2. Types
2.4.2.2.1. Qualitative
2.4.2.2.2. Quantitative

2.4.2.3. Advantages

2.4.2.4. Techniques
2.4.2.4.1. Interviews
2.4.2.4.2. Surveys
2.4.2.4.3. Focus Groups
2.4.2.4.4. Observational Research
2.4.2.4.5. Social Media Interactions

2.4.2.5. Stakeholders
2.4.2.5.1. Company Executives (CXOs)
2.4.2.5.2. Board of Directors
2.4.2.5.3. Company Presidents and Vice Presidents
2.4.2.5.4. Key Opinion Leaders
2.4.2.5.5. Research and Development Heads
2.4.2.5.6. Technical Experts
2.4.2.5.7. Subject Matter Experts
2.4.2.5.8. Scientists
2.4.2.5.9. Doctors and Other Hospitals

2.4.2.6. Ethics and Integrity
2.4.2.6.1. Research Ethics
2.4.2.6.2. Data Integrity

2.4.3. Analytical Tools and Databases

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Forecast Methodology
3.1.1. Top-Down Approach
3.1.2. Bottom-Up Approach
3.1.3. Hybrid Approach

3.2. Market Assessment Framework
3.2.1. Total Addressable Market (TAM)
3.2.2. Serviceable Addressable Market (SAM)
3.2.3. Serviceable Obtainable Market (SOM)
3.2.4. Currently Acquired Market (CAM)

3.3. Forecasting Tools and Techniques
3.3.1. Qualitative Forecasting
3.3.2. Correlation
3.3.3. Regression
3.3.4. Time Series Analysis
3.3.5. Extrapolation
3.3.6. Convergence
3.3.7. Forecast Error Analysis
3.3.8. Data Visualization
3.3.9. Scenario Planning
3.3.10. Sensitivity Analysis

3.4. Key Considerations
3.4.1. Demographics
3.4.2. Market Access
3.4.3. Reimbursement Scenarios
3.4.4. Industry Consolidation

3.5. Robust Quality Control
3.6. Key Market Segmentations
3.7. Limitations

4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage
4.2.2.1. Overview of Major Currencies Affecting the Market
4.2.2.2. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Exchange Impact
4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession
4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates
4.2.6.1. Overview of Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario

4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. R&D Innovation
4.2.11.7. Stock Market Performance
4.2.11.8. Supply Chain
4.2.11.9. Cross-Border Dynamics

5. EXECUTIVE SUMMARY

6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of Immuno-Oncology Drugs Market
6.2.1. Key Characteristics of Immuno-Oncology Drugs
6.2.2. Key Applications of the Immuno-Oncology Drugs
6.2.3. Challenges Associated with Immuno-Oncology Drugs

6.3. Future Perspective

7. COMPETITIVE LANDSCAPE
7.1. Chapter Overview
7.2. Immuno-Oncology Drug Developers: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters

7.2.4. Immuno-Oncology Drugs Market: Overall Market Landscape
7.2.4.1. Analysis by Drug Type
7.2.4.2. Analysis by Mode of Action Type
7.2.4.3. Analysis by Route of Administration Type
7.2.4.4. Analysis by Therapeutic Application Type
7.2.4.5. Analysis by Distribution Channel Type
7.2.4.6. Analysis by End User

8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodologies

8.4. Company Competitiveness Analysis: Immuno-Oncology Drugs Market Providers
8.4.1. Immuno-Oncology Drug Developers Based in North America (Peer Group 1)
8.4.2. Immuno-Oncology Drug Developers Based in Europe (Peer Group 2)
8.4.3. Immuno-Oncology Drug Developers Based in Asia-Pacific (Peer Group 3)
8.4.4. Immuno-Oncology Drug Developers Based in Middle East and North Africa, and Latin America (Peer Group 4)

8.5. Key Findings

9. COMPANY PROFILES
9.1. Chapter Overview
9.2. AstraZeneca
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. Service / Product Portfolio
9.2.4. Recent Developments and Future Outlook

* Similar details are presented for other below mentioned companies based on information in the public domain

9.3. Amgen
9.4. AbbVie
9.5. Bristol Myers Squibb Company
9.6. Bayer
9.7. Bluebird
9.8. Coloplast
9.9. Eli Lilly
9.10. Fresenius
9.11. Genentech
9.12. GSK
9.13. Ipsen
9.14. Johnson & Johnson
9.15. Merck
9.16. Novartis
9.17. Pfizer
9.18. Regeneron Pharmaceuticals
9.19. Roche
9.20. Sanofi

10. SWOT ANALYSIS

11. MARKET IMPACT ANALYSIS
11.1. Chapter Overview
11.2. Market Drivers
11.3. Market Restraints
11.4. Market Opportunities
11.5. Market Challenges
11.6. Conclusion

12. GLOBAL IMMUNO-ONCOLOGY DRUGS MARKET
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Trends Disruption Impacting Market
12.4. Global Immuno-Oncology Drugs Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

12.5. Multivariate Scenario Analysis
12.5.1. Conservative Scenario
12.5.2. Optimistic Scenario

12.6. Key Market Segmentations

13. MARKET OPPORTUNITIES BASED ON TYPE OF DRUG
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Revenue Shift Analysis
13.4. Market Movement Analysis
13.5. Penetration-Growth (P-G) Matrix
13.6. Immuno-Oncology Drugs Market for Immune Checkpoint Inhibitors: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.7. Immuno-Oncology Drugs Market for Immune System Modulators: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.8. Immuno-Oncology Drugs Market for Monoclonal Antibodies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.9. Immuno-Oncology Drugs Market for Cancer Vaccines: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.10. Immuno-Oncology Drugs Market for Others: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.11. Data Triangulation and Validation

14. MARKET OPPORTUNITIES BASED ON MODE OF ACTION
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Revenue Shift Analysis
14.4. Market Movement Analysis
14.5. Penetration-Growth (P-G) Matrix
14.6. Immuno-Oncology Drugs Market for Immune Checkpoint Blockade: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.7. Immuno-Oncology Drugs Market for Immune Stimulants: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.8. Immuno-Oncology Drugs Market for Cellular Immunotherapy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.9. Immuno-Oncology Drugs Market for Targeted Therapy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.10. Immuno-Oncology Drugs Market for Regulatory T-Cell Modulators: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.11. Data Triangulation and Validation

15. MARKET OPPORTUNITIES BASED ON ROUTE OF ADMINISTRATION
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Revenue Shift Analysis
15.4. Market Movement Analysis
15.5. Penetration-Growth (P-G) Matrix
15.6. Immuno-Oncology Drugs Market for Intravenous (IV): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.7. Immuno-Oncology Drugs Market for Subcutaneous: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.8. Immuno-Oncology Drugs Market for Oral: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.9. Immuno-Oncology Drugs Market for Intramuscular: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.10. Immuno-Oncology Drugs Market for Intralesional: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.11. Data Triangulation and Validation

16. MARKET OPPORTUNITIES BASED ON THERAPEUTIC AREA
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Revenue Shift Analysis
16.4. Market Movement Analysis
16.5. Penetration-Growth (P-G) Matrix
16.6. Immuno-Oncology Drugs Market for Melanoma: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.7. Immuno-Oncology Drugs Market for Lung Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.8. Immuno-Oncology Drugs Market for Blood Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.9. Immuno-Oncology Drugs Market for Renal Cell Carcinoma: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.10. Immuno-Oncology Drugs Market for Bladder Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.11. Immuno-Oncology Drugs Market for Other Therapeutic Applications: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.12. Data Triangulation and Validation

17. MARKET OPPORTUNITIES BASED ON TYPE OF DISTRIBUTION CHANNEL
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Revenue Shift Analysis
17.4. Market Movement Analysis
17.5. Penetration-Growth (P-G) Matrix
17.6. Immuno-Oncology Drugs Market for Hospital Pharmacies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.7. Immuno-Oncology Drugs Market for Retail Pharmacies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.8. Immuno-Oncology Drugs Market for Online Pharmacies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.9. Data Triangulation and Validation

18. MARKET OPPORTUNITIES BASED ON TYPE OF END USER
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Revenue Shift Analysis
18.4. Market Movement Analysis
18.5. Penetration-Growth (P-G) Matrix
18.6. Immuno-Oncology Drugs Market for Hospitals: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.7. Immuno-Oncology Drugs Market for Clinics: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.8. Immuno-Oncology Drugs Market for Ambulatory Surgical Centers: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.9. Data Triangulation and Validation

19. MARKET OPPORTUNITIES FOR IMMUNO-ONCOLOGY DRUGS IN NORTH AMERICA
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Revenue Shift Analysis
19.4. Market Movement Analysis
19.5. Penetration-Growth (P-G) Matrix

19.6. Immuno-Oncology Drugs Market in North America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.6.1. Immuno-Oncology Drugs Market in the US: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.6.2. Immuno-Oncology Drugs Market in Canada: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.6.3. Immuno-Oncology Drugs Market in Mexico: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

19.7. Data Triangulation and Validation

20. MARKET OPPORTUNITIES FOR IMMUNO-ONCOLOGY DRUGS IN EUROPE
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Revenue Shift Analysis
20.4. Market Movement Analysis
20.5. Penetration-Growth (P-G) Matrix

20.6. Immuno-Oncology Drugs Market in Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.6.1. Immuno-Oncology Drugs Market in Germany: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.6.2. Immuno-Oncology Drugs Market in France: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.6.3. Immuno-Oncology Drugs Market in Italy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.6.4. Immuno-Oncology Drugs Market in Spain: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.6.5. Immuno-Oncology Drugs Market in the UK: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.6.6. Immuno-Oncology Drugs Market in Rest of Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.7. Data Triangulation and Validation

21. MARKET OPPORTUNITIES FOR IMMUNO-ONCOLOGY DRUGS IN ASIA-PACIFIC
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Revenue Shift Analysis
21.4. Market Movement Analysis
21.5. Penetration-Growth (P-G) Matrix

21.6. Immuno-Oncology Drugs Market in Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.6.1. Immuno-Oncology Drugs Market in China: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.6.2. Immuno-Oncology Drugs Market in India: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.6.3. Immuno-Oncology Drugs Market in Japan: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.6.4. Immuno-Oncology Drugs Market in South Korea: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.6.5. Immuno-Oncology Drugs Market in Rest of the Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

21.7. Data Triangulation and Validation

22. MARKET OPPORTUNITIES FOR IMMUNO-ONCOLOGY DRUGS IN MIDDLE EAST AND NORTH AFRICA (MENA)
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Revenue Shift Analysis
22.4. Market Movement Analysis
22.5. Penetration-Growth (P-G) Matrix

22.6. Immuno-Oncology Drugs Market in Middle East and North Africa (MENA): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.6.1. Immuno-Oncology Drugs Market in Egypt: Historical Trends (Since 2020) and Forecasted Estimates (Till 205)
22.6.2. Immuno-Oncology Drugs Market in Saudi Arabia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.6.3. Immuno-Oncology Drugs Market in United Arab Emirates (UAE): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

22.7. Data Triangulation and Validation

23. MARKET OPPORTUNITIES FOR IMMUNO-ONCOLOGY DRUGS IN LATIN AMERICA
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Revenue Shift Analysis
23.4. Market Movement Analysis
23.5. Penetration-Growth (P-G) Matrix

23.6. Immuno-Oncology Drugs Market in Latin America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.1. Immuno-Oncology Drugs Market in Argentina: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.2. Immuno-Oncology Drugs Market in Brazil: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

23.7. Data Triangulation and Validation

24. APPENDIX 1: TABULATED DATA

25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

26. CUSTOMIZATION OPPORTUNITIES

27. ROOTS SUBSCRIPTION SERVICES

28. AUTHOR DETAIL